.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Baxter
Farmers Insurance
Healthtrust
Mallinckrodt
Moodys
Chinese Patent Office
Cipla
Federal Trade Commission
Cerilliant

Generated: December 14, 2017

DrugPatentWatch Database Preview

Helsinn Hlthcare Company Profile

« Back to Dashboard

What is the competitive landscape for HELSINN HLTHCARE, and when can generic versions of HELSINN HLTHCARE drugs launch?

HELSINN HLTHCARE has three approved drugs.

There are eighteen US patents protecting HELSINN HLTHCARE drugs.

There are one hundred and seventy-seven patent family members on HELSINN HLTHCARE drugs in sixty-three countries and fourteen supplementary protection certificates in ten countries.

Summary for Helsinn Hlthcare

International Patents:177
US Patents:18
Tradenames:2
Ingredients:2
NDAs:3
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Helsinn HlthcareALOXIpalonosetron hydrochlorideINJECTABLE;INTRAVENOUS021372-002Feb 29, 2008APRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Helsinn HlthcareALOXIpalonosetron hydrochlorideINJECTABLE;INTRAVENOUS021372-002Feb 29, 2008APRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Helsinn HlthcareALOXIpalonosetron hydrochlorideINJECTABLE;INTRAVENOUS021372-001Jul 25, 2003APRXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Helsinn HlthcareALOXIpalonosetron hydrochlorideINJECTABLE;INTRAVENOUS021372-002Feb 29, 2008APRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Helsinn HlthcareALOXIpalonosetron hydrochlorideINJECTABLE;INTRAVENOUS021372-001Jul 25, 2003APRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Helsinn HlthcareAKYNZEOnetupitant; palonosetron hydrochlorideCAPSULE;ORAL205718-001Oct 10, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Helsinn HlthcareAKYNZEOnetupitant; palonosetron hydrochlorideCAPSULE;ORAL205718-001Oct 10, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Helsinn HlthcareALOXIpalonosetron hydrochlorideINJECTABLE;INTRAVENOUS021372-001Jul 25, 2003APRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Helsinn HlthcareALOXIpalonosetron hydrochlorideINJECTABLE;INTRAVENOUS021372-002Feb 29, 2008APRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Helsinn HlthcareALOXIpalonosetron hydrochlorideINJECTABLE;INTRAVENOUS021372-001Jul 25, 2003APRXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Helsinn Hlthcare

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Helsinn HlthcareALOXIpalonosetron hydrochlorideCAPSULE;ORAL022233-001Aug 22, 2008► Subscribe► Subscribe
Helsinn HlthcareAKYNZEOnetupitant; palonosetron hydrochlorideCAPSULE;ORAL205718-001Oct 10, 2014► Subscribe► Subscribe
Helsinn HlthcareALOXIpalonosetron hydrochlorideINJECTABLE;INTRAVENOUS021372-002Feb 29, 2008► Subscribe► Subscribe
Helsinn HlthcareALOXIpalonosetron hydrochlorideINJECTABLE;INTRAVENOUS021372-001Jul 25, 2003► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Helsinn Hlthcare

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,479,483 4-phenyl-pyridine derivatives► Subscribe
9,308,266Liquid pharmaceutical formulations of palonosetron► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Helsinn Hlthcare Drugs

Country Document Number Estimated Expiration
Spain2623503► Subscribe
Japan5461763► Subscribe
Colombia6551693► Subscribe
Slovenia1035115► Subscribe
Japan5890780► Subscribe
Slovakia2352000► Subscribe
South Africa201203174► Subscribe
Netherlands300758► Subscribe
Czech Republic300596► Subscribe
European Patent Office2361090► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Helsinn Hlthcare Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
15/030Ireland► SubscribePRODUCT NAME: NETUPITANT OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF; REGISTRATION NO/DATE: EU/1/15/1001 20150527
1035115/01Switzerland► SubscribePRODUCT NAME: NETUPITANT; REGISTRATION NO/DATE: SWISSMEDIC 65499 06.11.2015
2015 00044Denmark► SubscribePRODUCT NAME: NETUPITANT; REG. NO/DATE: EU/1/15/1001 20150527
745Luxembourg► SubscribePRODUCT NAME: NETUPITANT/PALONOSETRON ET LEURS DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (AKYNZEO); FIRST REGISTRATION: 20150527
C0049France► SubscribePRODUCT NAME: NETUPITANT OU L'UN DE SES SELS D'ADDITION D'ACIDES PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/15/1001 20150529
90040-0Sweden► SubscribePRODUCT NAME: NETUPITANT; REG. NO/DATE: EU/1/15/1001 20150529
00758Netherlands► SubscribePRODUCT NAME: NETUPITANT, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH; REGISTRATION NO/DATE: EU/1/15/1001 20150527
2015036Lithuania► SubscribePRODUCT NAME: NETUPITANTUM; REGISTRATION NO/DATE: EU/1/15/1001 20150527
2015036,C1035115Lithuania► SubscribePRODUCT NAME: NETUPITANTAS; REGISTRATION NO/DATE: EU/1/15/1001 20150527
2015 00044Denmark► SubscribePRODUCT NAME: NETUPITANT; REG. NO/DATE: EU/1/15/1001 20150529
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Federal Trade Commission
QuintilesIMS
Teva
Chinese Patent Office
US Department of Justice
Farmers Insurance
Express Scripts
McKinsey
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot